



Laboratory Investigation Report

Patient Name	: Mrs. Neeraj Pasricha	Centre	: 910 - Max Hospital - Saket M S S H
Age/Gender	: 57 Y 8 M 12 D /F	OP/IP No/UHID	: IP/235368/3220D/
MaxID/Lab ID	: SKDD.973461/0628042323700	Collection Date/Time	: 29/Apr/2023 01:20AM
Ref Doctor	: Dr.Puneet Agarwal	Reporting Date/Time	: 01/May/2023 05:31PM

Molecular Diagnostics



Myeloproliferative Neoplasia Profile(MPN) with BCR

Test Name	Result	Unit	Bio Ref Interval
-----------	--------	------	------------------

MPN Reflex Panel

Jak2 V617F	Not Detected		
Jak2 Exon 12	Not Detected		
CALR	Not Detected		
MPL	Not Detected		

NOTE

1. This is an in-house developed assay.
2. Indeterminate / Not detected result does not rule out the presence of mutation as it may be below the detection limits of the assay
3. This assay detects JAK2 only V617F mutation (LOD 2%), insertions and deletions in exon 12 of JAK2 gene (LOD 10%), frameshift mutations in exon 9 of the calreticulin (CALR) gene (LOD 10%) and W515L, W515K, W515A, and S505N mutations in exon 10 of MPL gene (LOD 10%).
4. Test conducted on Whole blood / Bone Marrow.

COMMENTS

Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or platelets are produced in the bone marrow. MPNs are characterised by somatic recurrent mutations and are included as the main criteria in the 2008 WHO classification. JAK2 V617F mutations account for the majority of patients with Polycythemia Vera (PV) (more than 90%) and 60% of patients with Essential Thrombocythemia (ET) or Myelofibrosis (MF). Several somatic mutations of JAK2 exon 12 can be found in a myeloproliferative disorder that is mainly characterized by erythrocytosis. Abnormalities (deletions/duplications/substitutions) located in exon 12 of JAK2 are detected exclusively in 2%–4% of PV (ESMO Guidelines, 2015). The vast majority of patients with PV harbor a mutation in JAK2, with JAK2 V617F seen in around 97% and mutations in JAK2 exon 12 found in remainder. Frameshift mutations in exon 9 of the calreticulin gene (CALR) are reported in approximately 20% to 35% of all patients with Essential Thrombocythemia (ET) and Myelofibrosis (MF) (accounting for approximately 60%–80% of patients with JAK2/MPL-negative ET and MF)

USAGE

1. This is a qualitative assay for patients.
2. The diagnosis of MPN is based on the 2017 WHO Criteria and requires a combination of clinical, laboratory, cytogenetic, and molecular tests.

Kindly correlate with clinical findings

*** End Of Report ***

Test Performed at :910 - Max Hospital - Saket M S S H, Press Enclave Road, Mandir Marg, Saket, New Delhi, Delhi 110017

Page 1 of 2

Booking Centre :910 - Max Hospital - Saket M S S H, Press Enclave Road, Mandir Marg, Saket, New Delhi, Delhi 110017, 9090909090

The authenticity of the report can be verified by scanning the Q R Code on top of the page

Max Lab Limited (A Wholly Owned Subsidiary of Max Healthcare Institute Ltd.)

Max Super Speciality Hospital, Saket (West Block), 1, Press Enclave Road, Saket, New Delhi - 110 017, Phone: +91-11-6611 5050

(CIN No.: U85100DL2021PLC381826)

Helpline No. 7982 100 200 www.maxlab.co.in feedback@maxlab.co.in

Conditions of Reporting: 1. The tests are carried out in the lab with the presumption that the specimen belongs to the patient name as identified in the bill/test request form. 2. The test results relate specifically to the sample received in the lab and are presumed to have been generated and transported per specific instructions given by the physicians/laboratory. 3. The reported results are for the information and interpretation by the referring doctor only. 4. Some tests are referred to other laboratories to provide a wider test menu to the customer. 5. Max Healthcare shall in no event be liable for accidental damages loss, or destruction of specimen which is not attributable to any direct and mala fide act or omission of Max Healthcare or its employees. Liability of Max Healthcare for deficiency of services, or other errors and omissions shall be limited to fee paid by the patient for the relevant laboratory services.



MC-2714



Laboratory Investigation Report

Patient Name	: Mrs. Neeraj Pasricha	Centre	: 910 - Max Hospital - Saket M S S H
Age/Gender	: 57 Y 8 M 12 D /F	OP/IP No/UHID	: IP/235368/3220D/
MaxID/Lab ID	: SKDD.973461/0628042323700	Collection Date/Time	: 29/Apr/2023 01:20AM
Ref Doctor	: Dr.Puneet Agarwal	Reporting Date/Time	: 01/May/2023 05:31PM

Molecular Diagnostics



SIN No:MS0804675

Myeloproliferative Neoplasia Profile(MPN) with BCR

Test Name	Result	Unit	Bio Ref Interval
-----------	--------	------	------------------



Dr. Nitin Dayal, M.D.
Principal Consultant & Head,
Haematopathology



Dr Atul Thatai, Ph.D
Director
Molecular and Cyto Genomics

Test Performed at :910 - Max Hospital - Saket M S S H, Press Enclave Road, Mandir Marg, Saket, New Delhi, Delhi 110017

Booking Centre :910 - Max Hospital - Saket M S S H, Press Enclave Road, Mandir Marg, Saket, New Delhi, Delhi 110017, 9090909090

The authenticity of the report can be verified by scanning the Q R Code on top of the page

